Cite

HARVARD Citation

    Kudrow, D. et al. (n.d.). P.032 Long-term safety and tolerability of eptinezumab in patients with chronic migraine: A 2-year, open-label, phase 3 trial. Canadian journal of neurological sciences. p. S29. [Online]. 
  
Back to record